A majority with overweight/obesity discontinue within a year, but the rate is higher among those without type 2 diabetes.

Several years ago, a little-known drug named Ozempic—previously used only to treat diabetes—emerged as a promising new drug ...

Nearly 2 in 3 people without diabetes quit popular weight loss drugs such as Ozempic or Victoza within one year, according to ...

Companies such as Teladoc and Omada Health have embraced GLP-1s while dangling the prospect of lowered costs to their ...

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy, but risk is elevated in the first year of treatment, according to a ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

A recent review shows who newer medications for type 2 diabetes may help the most, particularly in reducing the risk of cardiovascular disease.

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Lexaria Bioscience (LEXX) announces that dosing has begun in its fluorescently tagged DehydraTECH-semaglutide rodent biodistribution study. The ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

GLP-1 drugs mimic a hormone that sends the brain signals of fullness. Researchers theorize that the drugs could work the same ...

Weight loss drugs like Ozempic and Wegovy have been tied in a large, national study to a drop in the risk of developing ...